Beyond the Batch Paradigm
Pharmaceutical tablet manufacturing has been batch-based for most of its history. Raw materials in, process step by step, finished product out, test and release. The batch is a defined, auditable unit of production with a clear beginning and end.
Continuous manufacturing challenges that model. Materials flow through an integrated process train without stopping: blending, granulation, drying, tabletting, and coating happen in sequence, in real time, monitored by inline sensors that provide a continuous stream of data on the product being made. There is no batch in the traditional sense. There is a time-defined unit of production, characterised by the process data collected during its manufacture.
The FDA has actively encouraged this transition. Its 2019 guidance on pharmaceutical quality for continuous manufacturing and the ICH Q13 guideline both provide frameworks that make continuous manufacturing a viable regulatory pathway for new products.
The Real Advantages of Continuous Over Batch
Smaller Footprint, Faster Output
A continuous manufacturing line produces tablets at a defined throughput rate, typically measured in kilograms per hour. To increase output, you run the line for longer, not build a bigger facility. For clinical supply, this means small campaigns can be run efficiently without the scale-up losses inherent in batch tabletting. For commercial supply, it means flexible throughput without capital investment in larger equipment.
Better Process Understanding
Because continuous manufacturing relies on real-time sensors, the process data generated per batch equivalent is orders of magnitude richer than in conventional manufacturing. Blend uniformity, particle size, tablet hardness, and dissolution are all monitored continuously rather than sampled at fixed intervals. This data density enables faster identification of process drift and more rapid root-cause analysis when deviations occur.
Reduced Scale-Up Risk
In batch manufacturing, scaling from a development batch to a commercial batch means different equipment, different shear forces, different mixing dynamics. In continuous manufacturing, the same equipment runs at the same process parameters regardless of the total batch size. Scale-up is a matter of runtime, not equipment change. That removes one of the most unpredictable phases of pharmaceutical development.
Is Your Product a Candidate? A Practical Checklist
| Factor | Favourable for Continuous Manufacturing | Less Favourable |
| API flow properties | Good to moderate flowability; amenable to loss-in-weight feeding | Very poor flow; tendency to bridge or rat-hole in feeders |
| Blend sensitivity | Blend uniformity maintained under continuous mixing conditions | Very segregation-prone blends; sticky or cohesive powders |
| Granulation requirement | Direct compression or dry granulation preferred; wet granulation possible on integrated lines | Products requiring aqueous wet granulation with long drying times |
| Dose and tablet size | Mid-range doses; standard tablet geometries | Very low dose (microgram range) where blend uniformity at feeder level is challenging |
| Development stage | New development with flexibility to design process for continuous manufacturing from the start | Established batch process with significant existing clinical data package |
| Regulatory timeline | Sufficient time to generate continuous manufacturing process data for CMC filing | Accelerated timeline where batch process is faster to validate |
The Regulatory Pathway for Continuous Manufacturing
ICH Q13, finalised in 2022, provides the harmonised guidance for continuous manufacturing of drug substances and drug products. It addresses the definition of batch, the control strategy for continuous processes, the use of PAT tools for real-time release, and the stability data requirements. The FDA’s own guidance on continuous manufacturing complements Q13 with US-specific expectations on process validation and real-time release testing.
For sponsors considering continuous manufacturing for a new programme, engaging with the regulatory agency early, through a Type B meeting with the FDA or a scientific advice procedure with the EMA, is the most reliable way to confirm that the proposed control strategy and batch definition approach will be accepted before significant development investment is made.
Ardena’s Oral Solid Manufacturing Capabilities at Ghent
Ardena’s oral solid manufacturing team at Ghent has both batch and continuous manufacturing capability, with experience developing control strategies and CMC packages that meet the regulatory expectations for both approaches. The team can advise on whether a specific product profile is suited to continuous manufacturing and help design a development programme that builds the process understanding needed for a regulatory filing.
